Treatment with ICOS antibody alone has previously been shown to result in regulatory T cell depletion in the tumor environment in preclinical studies35, and consistent with those findings, we show significantly fewer regulatory T cells in the tumor environment with ICOS antibody alone. The gene discussed is ICOS; the disease is neoplasm.